XORTX Therapeutics Inc. (NASDAQ:XRTX) Stock Short Interest Report for October

XORTX Therapeutics Inc. (NASDAQ:XRTX) was the recipient of a large growth in short interest in the month of October. As of October 15th, there was short interest totaling 237,048 shares, a growth of 285.2% from the September 30th total of 61,535 shares. Currently, 14.0% of the shares of the company are short sold. Based on an average daily trading volume, of 2,819,981 shares, the days-to-cover ratio is presently 0.1 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of XORTX Therapeutics in a research note on Monday, September 21st. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, XORTX Therapeutics has a consensus rating of “Sell”.

XORTX Therapeutics Price Performance

Shares of XRTX opened at $1.10 on Wednesday. The stock has a market capitalization of $2.00 million, a price-to-earnings ratio of -0.40 and a beta of 0.78. XORTX Therapeutics has a 1 year low of $0.83 and a 1 year high of $3.65. The business’s 50 day simple moving average is $1.79 and its 200-day simple moving average is $2.16.

XORTX Therapeutics (NASDAQ:XRTX) last announced its quarterly earnings results on Saturday, August 15th. The technology company reported ($1.05) earnings per share for the quarter.

About XORTX Therapeutics

XORTX Therapeutics Inc (NASDAQ:XRTX) is a clinical-stage pharmaceutical company focused on developing therapies for conditions associated with dysregulated uric acid metabolism. The company’s research is centered on inhibiting xanthine oxidase, an enzyme involved in uric acid production, with the goal of addressing kidney and other serious chronic diseases.

XORTX’s development programs include XRx-008, an orally administered therapy being developed for autosomal dominant polycystic kidney disease, a genetic disorder that can progressively impair kidney function.